financetom
Business
financetom
/
Business
/
Mainz Biomed Prices $3 million Follow-on Offering at $1.35 per Unit
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mainz Biomed Prices $3 million Follow-on Offering at $1.35 per Unit
Aug 4, 2025 8:36 AM

11:11 AM EDT, 08/04/2025 (MT Newswires) -- Mainz Biomed ( MYNZ ) said Monday it has priced a $3 million follow-on offering of 2.2 million units comprising shares and warrants at an offer price of $1.35 per unit.

Each unit will comprise one share or a prefunded warrant and one Series A warrant for the purchase of one and one-half shares, the company said.

The Series A warrants are immediately exercisable at $1.35 per share and will expire five years from the issue date, Mainz Biomed ( MYNZ ) said.

Price: 1.41, Change: +0.08, Percent Change: +6.02

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
GoldHaven Says Copecal Gold Project in Brazil Holds 'Strong Potential' for Gold Mineralization
GoldHaven Says Copecal Gold Project in Brazil Holds 'Strong Potential' for Gold Mineralization
Feb 10, 2025
08:16 AM EST, 02/10/2025 (MT Newswires) -- GoldHaven Resources ( GHVNF ) on Monday said its 100%-owned Copecal Gold Project in Brazil holds strong potential for gold mineralization as it has a solid foundation of historic exploration data, favorable geological setting, and a systematic exploration strategy. Exploration work conducted by AngloGold Ashanti from 2010 to 2016 had uncovered multiple gold-bearing...
Satellos Bioscience Completes Enrollment of All Dose Cohorts for Phase 1 SAT-3247 Trial
Satellos Bioscience Completes Enrollment of All Dose Cohorts for Phase 1 SAT-3247 Trial
Feb 10, 2025
08:17 AM EST, 02/10/2025 (MT Newswires) -- Satellos Bioscience ( MSCLF ) on Monday said it has completed enrollment of all four multiple-ascending dose cohorts for the Phase 1 clinical trial of SAT-3247 in healthy volunteers. SAT-3247 is a small molecule drug being developed by Satellos to regenerate skeletal muscle which is lost in Duchenne muscular dystrophy (DMD) and other...
Hain Celestial Explores Strategic Options for Personal Care Business
Hain Celestial Explores Strategic Options for Personal Care Business
Feb 10, 2025
08:18 AM EST, 02/10/2025 (MT Newswires) -- Hain Celestial Group ( HAIN ) said Monday it is exploring strategic options for its personal care business as it shifts focus to its better-for-you food and beverages portfolio. The company reported a 38% year-over-year decline in organic net sales for its personal care business for its fiscal Q2 ended Dec. 31. HAIN...
BRIEF-NXP Agrees To Acquire Edge AI Pioneer Kinara
BRIEF-NXP Agrees To Acquire Edge AI Pioneer Kinara
Feb 10, 2025
Feb 10 (Reuters) - NXP Semiconductors ( NXPI ): * NXP AGREES TO ACQUIRE EDGE AI PIONEER KINARA TO REDEFINE THE INTELLIGENT EDGE * NXP SEMICONDUCTORS NV ( NXPI ) - DEAL VALUED AT $307 MILLION, EXPECTED TO CLOSE IN H1 2025 Source text: Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved